-
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
Tuesday, October 26, 2021 - 8:07am | 238Read More...AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data. According to the data, a combo of Imfinzi (durvalumab) and chemotherapy significantly...
-
Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial
Friday, October 8, 2021 - 12:24pm | 253Read More...Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer) and multiple other solid tumors. The data were shared at the AACR-NCI-EORTC Molecular Targets Conference. Initial efficacy data...
-
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
Friday, July 9, 2021 - 9:47am | 210Read More...The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking approval for pemigatinib for cholangiocarcinoma. The FGFR1/2/3 inhibitor's application covers adults with previously...
-
FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer
Tuesday, June 1, 2021 - 8:02am | 271Read More...BridgeBio Pharma Inc (NASDAQ: BBIO), through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq (infigratinib) under the accelerated approval program for cholangiocarcinoma (CCA). The approval covers patients with previously...
-
Incyte's Pemazyre Wins European Approval For Bile Duct Cancer
Monday, March 29, 2021 - 2:34pm | 254Read More...The European Commission (EC) has approved Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, rare cancer that forms in the bile duct. The approval covers adults' treatment with locally advanced or metastatic cholangiocarcinoma with a...
